Research programme: purinergic receptor antagonists - Evotec

Drug Profile

Research programme: purinergic receptor antagonists - Evotec

Alternative Names: P2X7 receptor antagonists - Evotec; P2X2/3 antagonists; P2X2/3 antagonists - Evotec; P2X3 antagonists; P2X3 antagonists - Evotec

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Renovis
  • Developer Evotec AG
  • Class Small molecules
  • Mechanism of Action Purinergic P2 receptor antagonists; Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain; Urinary incontinence

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Urinary-incontinence in Germany
  • 06 Mar 2007 Preclinical trials in Urinary incontinence in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top